Schedule of Stock-Based Compensation Expense Classified in Research and Development Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Stock-based compensation expense	$ 4,814	$ 1,436
Sales And Marketing Expenses [Member]
Stock-based compensation expense	625	202
General and Administrative Expense [Member]
Stock-based compensation expense	4,002	1,124
Research and Development Expense [Member]
Stock-based compensation expense	187	110
Research and Development Expense [Member] | Lucid Diagnostics Inc [Member]
Stock-based compensation expense	3,835	805
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Sales And Marketing Expenses [Member]
Stock-based compensation expense	265
Lucid Diagnostics Inc 2018 Equity Plan [Member] | General and Administrative Expense [Member]
Stock-based compensation expense	3,201	789
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Research and Development Expense [Member]
Stock-based compensation expense	71	13
PAVmed Inc 2014 Equity Plan [Member] | Sales And Marketing Expenses [Member]
Stock-based compensation expense	175
PAVmed Inc 2014 Equity Plan [Member] | General and Administrative Expense [Member]
Stock-based compensation expense	68
PAVmed Inc 2014 Equity Plan [Member] | Research and Development Expense [Member]
Stock-based compensation expense	$ 55	$ 3